Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-06-19
2007-06-19
Switzer, Juliet C. (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C536S024320, C536S024300, C536S023100
Reexamination Certificate
active
10121483
ABSTRACT:
Methods for detecting cancer that include hybridizing a set of chromosomal probes to a biological sample obtained from a patient, and identifying if aneusomic cells are present in a selected subset of cells obtained from the biological sample are described. A set of chromosomal probes and kits for detecting cancer that include sets of chromosomal probes, are also described.
REFERENCES:
patent: 5028525 (1991-07-01), Gray et al.
patent: 5447841 (1995-09-01), Gray et al.
patent: 5491224 (1996-02-01), Bittner et al.
patent: 5624819 (1997-04-01), Skolnick et al.
patent: 5665549 (1997-09-01), Pinkel et al.
patent: 5756696 (1998-05-01), Gray et al.
patent: 5776688 (1998-07-01), Bittner et al.
patent: 5856089 (1999-01-01), Wang et al.
patent: 5874234 (1999-02-01), Pasternack
patent: 6174681 (2001-01-01), Halling et al.
patent: 6376188 (2002-04-01), Halling et al.
patent: 1 035 215 (2000-09-01), None
patent: WO 95/13398 (1995-05-01), None
patent: WO 98/38333 (1998-09-01), None
Cambio Product Catalog, available online at www.ecogen.com/cambio.htm, Copyright 1997, accessed by the examiner Oct. 3, 2003.
Ried et al. (PNAS USA, vol. 89, p. 1388-1392).
Yokogi et al. (British Journal of Urology (1996) 78, 699-703).
Reeder et al. (Journal of Urology, vol. 158(5),pp. 1717-1721, 1997; internet print out provided with pp. numbered 1-11).
Sergers et al. (The Journal of Pathology (Feb. 1995) vol. 175, No. 2, pp. 219-226).
Xio et al. (Aug. 3, 1995) vol. 11, No. 3, p. 511-515).
Ahmann et al., “A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies,”Cancer Genetics and Cytogenetics, 1998, 101:7-11.
Alcaraz et al., “Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer,”Cancer Res., 1994, 54:3998-4002.
Cajulis et al., “Interphase cytogenetics as an adjunct in the cytodiagnosis of urinary bladder carcinoma. A comparative study of cytology, flow cytometry and interphase cytogenetics in bladder washes,”Anal. Quant. Cytol. Histol., 1994, 16(1):1-10.
Cajulis et al., “Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study,”Diagn. Cytopathol., 1995, 13(3):214-224.
Ellis et al., “Clinical Evaluation of the BTA Trak Assay and Comparison to Voided Urine Cytology and the Bard BTA Test in Patients with Recurrent Bladder Tumors,”Urology, 1997, 50(6):882-887.
Florentine et al., “Detection of Hyperdiploid Malignant Cells in Body Cavity Effusions by Fluorescence In Situ Hybridization on ThinPrep Slides,”Cancer, 1997, 81(5):299-308.
Halling et al., “A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma,”J. Urol., 2000, 164(5):1768-1775.
Landman et al., “Sensitivity and Specificity of NMP-22, Telomerase, and BTA in the Detection of Human Bladder Cancer,”Urology, 1998, 52(3):398-402.
Li et al., “Chromosome 3 Allelic Losses and Microsatellite Alterations in Transitional Cell Carcinoma of the Urinary Bladder,”Am. J. Pathol., 1996, 149(1):229-235.
Macoska et al., “Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer,”Cancer Res., 1994, 54:3824-3830.
Mao et al., “Molecular Detection of Primary Bladder Cancer by Microsatellite Analysis,”Science, 1996, 271(5249):659-662.
Matsuyama et al., “Nonrandom Numerical Aberrations of Chromosomes 7, 9, and 10 in DNA-Diploid Bladder Cancer,”Cancer Genetics and Cytogenetics, 1994, 77(2):118-124.
Mayfield et al., “Bladder tumors detected on screening: results at 7 years,”Brit. J. Urology, 1998, 82(6):825-828.
Meloni et al., “A New Approach in the Diagnosis and Follow-up of Bladder Cancer,”Cancer Genet. Cytogenet., 1993, 71:105-118.
Messing et al., “Comparison of Bladder Cancer Outcome in Men Undergoing Hematuria Home Screening Versus Those with Standard Clinical Presentations,”Urology, 1995, 45(3):387-397.
Moore et al., “Use of Fluorescence In Situ Hybridization to Detect Chromosome-Specific Changes in Exfoliated Human Bladder and Oral Mucosa Cells,”Environ. Mol. Mutagenesis, 1993, 22:130-137.
Nath et al., “Fluorescence in Situ Hybridization (FISH): DNA Probe Production and Hybridization Cirteria,”Biotechnic Histochem., 1998, 73(1):6-22.
Persons et al., “Chromosome-specific aneusomy in carcinoma of the breast,”Clin. Cancer Res., 1996, 2:883-888.
Pycha et al., “Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer,”J. Urol., 1997, 157(6):2116-2119.
Ramaekers et al., “Detection of genetic aberrations in bladder cancer using in situ hybridization,”Ann. N.Y. Acad. Sci., 1993, 677:199-213.
Sauter et al., “Y Chromosome Loss Detected by FISH in Bladder Cancer,”Cancer Genet. Cytogenet., 1995, 82(2):163-169.
Sauter et al., “Chromosome -9 Loss Detected by Fluorescence in situ Hybridization in Bladder Cancer,”Int. J. Cancer(Pred. Oncol., 1995, 64:99-103.
Sauter et al., “DNA aberrations in urinary bladder cancer detected by flow cytometry and FISH,”Urolog. Res., 1997, 25(Suppl. 1):S37-S43.
Sokolova et al., “The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine,”J. Mol. Diag., 2000, 2(3):116-123.
Waldman et al., “Centromeric Copy Number of Chomosome 7 Is Strongly Correlated with Tumor Grade and Labeling Index in Human Bladder Cancer,”Cancer Research, 1991, 51(14):3807-3813.
Wheeless et al., “Bladder Irrigation Specimens Assayed by Fluorescence In Situ Hybridization to Interphase Nuclei,”Cytometry, 1994, 17(4):319-326.
Yokogi et al., “Genomic heterogeneity in bladder cancer as detected by fluorescence in situ hybridization,”Brit. J. Urology, 1996, 78(5):699-703.
Zhang et al., “Interphase Cytogenetics of Workers Exposed to Benzene,”Environ. Health Perspect., 1996, 104(Suppl. 6):1325-1329.
Zhang et al., “Toward the Validation of Aneusomy Detection by Fluorescence in Situ Hybridization in Bladder Cancer: Comparative Analysis with Cytology, Cytogenetics, and Clinical Features Predicts Recurrence and Defines Clinical Testing Limitations,”Clin. Cancer Res., 1997, 3(12):2317-2328.
Zojer et al., “Interphase fluorescence in situ hybridization improves the detection of malignant cells in effusions from breast cancer patients,”British J. Urol., 1997, 75(3):403-407.
Zojer et al., “Chromosomal imbalances in primary and metastatic pancreatic carcinoma as detected by interphase cytogenetics: basic findings and clinical aspects,”British J. Urol., 1998, 77(8):1337-1342.
Martin et al., “2 Dimensional Histograms of Nuclear Area and Nuclear Shape in Diagnosis of Astrocytomas and Glioblastomas,”Zentralblatt fuer Allgemeine Pathologie und Pathologische Anatomie, 1986, 131(2):137-42 (English Abstract only, provided by BIOSIS Database—Acc. No. PREV198682045777)).
Waldman et al., “Chromosomal and proliferative heterogeneity of primary breast cancers measured by in situ hybridization,”Proc. Am. Assoc. Cancer Res., 1991, 32:30, Abstract No. 179.
Bubendorf, et al., “Multiprobe FISH for Enhanced Detection of Bladder Cancer in Voided Urine Specimens and Bladder Washings,”Am. J. Clin. Pathol., 116(1):79-86 (2001).
Kipp et al., “Monitoring Intravesical Therapy for Superficial Bladder Cancer Using Fluorescence in situ Hybridization,”J. Urol., 173:401-404 (2005).
Konety, et al., “In-office urinary markers for bladder Ca: What's new,”Urology Times, vol. 32, No. 10, Jul. 2004.
Sarosdy, et al., “Clini
Halling Kevin C.
Jenkins Robert B.
King Walter
Seelig Steven A.
Sokolova Irina A.
Fish & Richardson P.C.
Mayo Foundation for Medical Education and Research
Switzer Juliet C.
Vysis, Inc.
LandOfFree
Method and probe set for detecting cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and probe set for detecting cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and probe set for detecting cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3850797